Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Shares Outstanding (Weighted Average) (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported Shares Outstanding (Weighted Average) over the past 10 years, most recently at $4.3 million for Q4 2023.

  • For Q4 2023, Shares Outstanding (Weighted Average) rose 3.76% year-over-year to $4.3 million; the TTM value through Dec 2023 reached $4.3 million, up 3.76%, while the annual FY2023 figure was $4.3 million, 3.76% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2023 was $4.3 million at Corbus Pharmaceuticals Holdings, up from $4.3 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $122.2 million in Q3 2021 and troughed at $4.1 million in Q4 2021.
  • A 5-year average of $47.6 million and a median of $62.8 million in 2019 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): surged 68.66% in 2021 and later crashed 96.59% in 2022.
  • Year by year, Shares Outstanding (Weighted Average) stood at $63.9 million in 2019, then grew by 22.28% to $78.1 million in 2020, then crashed by 94.76% to $4.1 million in 2021, then rose by 1.85% to $4.2 million in 2022, then rose by 3.76% to $4.3 million in 2023.
  • Business Quant data shows Shares Outstanding (Weighted Average) for CRBP at $4.3 million in Q4 2023, $4.3 million in Q3 2023, and $4.3 million in Q2 2023.